Egetis Therapeutics AB (0ABW) Financial Statements
Egetis Therapeutics AB Financial Overview
Egetis Therapeutics AB's market cap is currently $4.68B. The company's EPS TTM is $-1.01; its P/E ratio is -9.96; Egetis Therapeutics AB is estimated to report earnings on November 6, 2026, and the estimated EPS forecast is $-0.20. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 62.40M | $ 46.10M | $ 57.60M | $ 22.50M | $ 38.24M |
| Gross Profit | $ 12.40M | $ 34.50M | $ -146.90M | $ -120.10M | $ -58.28M |
| Operating Income | $ -346.90M | $ -329.40M | $ -324.80M | $ -198.10M | $ -105.68M |
| EBITDA | $ -343.20M | $ -317.30M | $ -319.10M | $ -191.00M | $ -101.90M |
| Net Income | $ -342.50M | $ -343.60M | $ -326.90M | $ -189.50M | $ -104.73M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 215.80M | $ 351.00M | $ 303.30M | $ 127.70M | $ 143.97M |
| Total Assets | $ 639.10M | $ 792.30M | $ 760.20M | $ 561.10M | $ 569.27M |
| Total Debt | $ 90.60M | $ 117.40M | $ 113.00M | $ 2.70M | $ 4.20M |
| Net Debt | $ -125.20M | $ -233.60M | $ -190.30M | $ -125.00M | $ -139.76M |
| Total Liabilities | $ 300.40M | $ 299.40M | $ 214.60M | $ 54.90M | $ 42.23M |
| Stockholders' Equity | $ 338.70M | $ 492.80M | $ 545.60M | $ 506.20M | $ 527.04M |
| Cash Flow | |||||
| Free Cash Flow | $ -268.60M | $ -227.90M | $ -278.40M | $ -173.50M | $ -130.28M |
| Operating Cash Flow | $ -267.10M | $ -227.90M | $ -278.40M | $ -173.50M | $ -130.11M |
| Investing Cash Flow | $ -2.80M | $ -1.20M | $ -100.00K | $ -1.70M | $ -5.96M |
| Financing Cash Flow | $ 140.00M | $ 270.90M | $ 458.90M | $ 155.70M | $ -8.90M |
Currency in SEK
